Skip to main content
Australia Edition
Tuesday, 27 July 2021

Oxford–AstraZeneca COVID-19 vaccine

Vaccine against COVID-19

Oxford–AstraZeneca COVID-19 vaccine
Oxford–AstraZeneca COVID-19 vaccine

The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, and sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for prevention of COVID-19. Developed by Oxford University and AstraZeneca, it is given by intramuscular injection, using as a vector the modified chimpanzee adenovirus ChAdOx1. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. Another analysis showed that, for symptomatic COVID-19 infection after the second dose, the vaccine is 66% effective against the Alpha variant, and 60% against the Delta variant.

0 shares 5 views

News coverage

Oxford–AstraZeneca COVID-19 vaccine media coverage


More coverage